Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer

Abstract

Central nervous system (CNS) metastases are a common complication in patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), resulting in a poor prognosis and limited treatment options. Treatment of CNS metastases requires a multidisciplinary approach, and the optimal treatment options and sequence of therapies are yet to be established. Many systemic therapies have poor efficacy in the CNS due to the challenges of crossing the blood‐brain barrier (BBB), creating a major unmet need for the development of agents with good BBB‐penetrating biopharmaceutical properties. Although the CNS penetration of first‐ and second‐generation EGFR tyrosine kinase inhibitors (TKIs) is generally low, EGFR‐TKI treatment has been shown to delay time to CNS progression in patients with CNS metastases from EGFR‐mutated disease. However, a major challenge with EGFR‐TKI treatment for patients with NSCLC is the development of acquired resistance, which occurs in most patients treated with a first‐line EGFR‐TKI. Novel EGFR‐TKIs, such as osimertinib, have been specifically designed to address the challenges of acquired resistance and poor BBB permeability and have demonstrated efficacy in the CNS. A rational, iterative drug development process to design agents that could penetrate the BBB could prevent morbidity and mortality associated with CNS disease progression. To ensure a consistent approach to evaluating CNS efficacy, special consideration also needs to be given to clinical trial endpoints.

Implications for Practice

Historically, treatment options for patients who develop central nervous system (CNS) metastases have been limited and associated with poor outcomes. The development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has improved outcomes for patients with EGFR‐mutated disease, and emerging data have demonstrated the ability of these drugs to cross the blood‐brain barrier and elicit significant intracranial responses. Recent studies have indicated a role for next‐generation EGFR‐TKIs, such as osimertinib, in the treatment of CNS metastases. In the context of an evolving treatment paradigm, treatment should be individualized to the patient and requires a multidisciplinary approach.

Abstract

摘要

在患有表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者中,中枢神经系统(CNS)转移是常见的并发症,可致预后不良并且治疗方案有限?CNS转移的治疗需要多学科方法,而最佳的治疗方案和治疗顺序还有待确定?由于存在穿越血脑屏障(BBB)的挑战,许多全身性治疗在CNS中疗效不佳,导致具有良好BBB穿透性生物制药的开发工作,远远未能满足人们的需求?虽然第一代和第二代EGFR酪氨酸激酶抑制剂(TKIs)的CNS渗透率普遍较低,但EGFR‐TKI治疗已显示延缓了EGFR突变的CNS转移患者的CNS进展?然而,获得性耐药是EGFR‐TKI治疗NSCLC患者的一个主要挑战,大多数接受一线EGFR‐TKI治疗的患者都存在这个问题?新的EGFR‐TKI(如Osimertinib)是专门用来解决获得性抗药性和BBB通透性差的难题,并在CNS中显示了疗效?一个可以穿透BBB的合理迭代的药物开发过程,可以防止CNS疾病进展相关的病损率和死亡率?为了确保评估CNS疗效的一致性,还需要特别考虑临床试验终点?

实践意义

一直以来,向出现中枢神经系统(CNS)转移的患者提供的治疗方案很有限,并且与不良预后相关?表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)的发展改善了EGFR突变患者的预后?已经开始有数据显示,这些药物能够跨越血脑屏障,并引起明显的颅内缓解?最近研究表明,新一代EGFR‐TKI(如osimertinib)在治疗CNS转移中起着重要作用?在不断发展的治疗模式中,治疗应针对患者实现个体化,并需要采取多学科方法?

Introduction

Central nervous system (CNS) metastases are common in patients with advanced non‐small cell lung cancer (NSCLC), with a higher incidence observed in patients with epidermal growth factor receptor (EGFR)‐mutated NSCLC, compared with patients with EGFR‐wild type disease, even when adjusted for differences in survival [1, 2]. In patients with EGFR‐mutated disease, the prevalence of brain metastases at first diagnosis is approximately 25%, increasing to around 40% of patients 2 years after diagnosis [3, 4]. Leptomeningeal metastases (LM), the spread of tumor cells into the cerebrospinal fluid (CSF) and the leptomeninges, occur in 9%–15% of patients with EGFR‐mutated disease [2, 5]. Concurrent brain metastases are common, with up 82% of patients with LM experiencing prior or current brain metastases [6, 7]. Brain metastases are associated with a significantly poorer prognosis [8, 9], and the median overall survival (OS) time for patients with LM is just 3.6–4.5 months, despite multimodality treatment [10, 11].

The treatment of CNS metastases is particularly challenging given the limited passage of molecules across the blood‐CSF barrier and blood‐brain barrier (BBB; Fig. 1). Many modern therapeutic agents, including most chemotherapies, are large hydrophilic molecules that are unable to cross the BBB [12, 13]. As such, systemic therapies tend to be ineffective against brain metastases, with response rates for chemotherapy ranging from 15% to 30% [13]. However, for patients with EGFR‐mutated disease, small molecule EGFR tyrosine kinase inhibitors (TKIs) have the potential to elicit CNS responses. This review aims to discuss preclinical and clinical evidence for EGFR‐TKIs in the treatment of CNS metastases, within the context of current treatment options.

Nontargeted Treatment Options for CNS Metastases

In the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC, recommended options for patients with fewer than three brain metastases include (a) stereotactic radiosurgery (SRS) or (b) surgical resection (if symptomatic or needed for diagnosis) followed by SRS or whole‐brain radiotherapy (WBRT) [14]. Although surgical resection was long considered the standard of care for solitary brain metastasis, SRS is equally as effective in extending patient survival [15]. Factors affecting the choice of surgery versus SRS include tumor size and location, systemic disease status, and the need for relief from symptomatic mass effect or edema [16]. SRS has been shown to be equally as effective in patients with 5–10 brain metastases, compared with patients with 2–4 brain metastases, indicating that SRS is also suitable for patients with extensive brain metastases [17]. However, although SRS provides a high local tumor control rate (84%–93%) [18, 19], it does not provide distant brain control [18, 20].

Traditionally, the NCCN Guidelines for NSCLC have recommended WBRT to target multiple metastases and prevent distant brain failure [21]; however, as extended survival is possible for patients with EGFR‐mutated disease, the treatment‐related toxicities associated with WBRT are of concern. Acute adverse effects, such as nausea and headache, are typically self‐limiting. However, late adverse effects (occurring months or years after treatment) such as neurocognitive decline, leukoencephalopathy, and radiation necrosis are irreversible and may have severe consequences [22, 23]. Results from a recent phase III trial indicate that the addition of WBRT to optimal supportive care does not significantly improve survival or quality of life for patients with brain metastases from NSCLC [24]. However, this study was not specific to patients with EGFR‐mutated disease, in whom the risk‐benefit assessment may differ due to improved systemic prognosis. In line with these results, the NCCN Guidelines for NSCLC have revised recommendations for the treatment of brain metastases by decreasing recommendations for WBRT [14].

There is a lack of standard treatments for patients with LM, from any type of primary cancer, due to insufficient evidence in the literature [25]. The NCCN Guidelines for CNS cancers recommend that patients with LM, from any primary cancer, be stratified into poor‐risk and good‐risk groups. The recommended treatment for patients in the poor‐risk group is palliative/best supportive care and to consider radiotherapy to symptomatic or painful sites for palliation. For patients in the good‐risk group, radiotherapy to bulky disease or symptomatic sites is recommended; a CSF flow scan is strongly recommended to direct further treatment. Depending on the results of CSF flow scans and CSF cytology, further treatment options include intra‐CSF chemotherapy, radiotherapy, and systemic chemotherapy [25].

EGFR‐TKIs

EGFR‐TKIs have a low molecular weight and the potential to cross the BBB more readily than most intravenous chemotherapies. However, first‐ and second‐generation EGFR‐TKIs generally have poor biopharmaceutical properties for BBB penetration due to their affinity for efflux transport proteins such as the adenosine triphosphate‐binding cassette subfamily members B1 and G2 (ABCB1 and ABCG2), hereafter referred to as permeability glycoprotein (P‐gp) and breast cancer‐resistance protein (BCRP), respectively [26-28] (Fig. 1). Preclinical studies have shown that uptake of EGFR‐TKIs in the brain is low because they do not readily cross the BBB [29, 30]. The CSF penetration of first‐ and second‐generation EGFR‐TKIs is generally low, with average CSF penetration rates of <1%, 1%–3%, and 3%–6% reported for afatinib, gefitinib, and erlotinib, respectively [31-34]. The CSF penetration of gefitinib is enhanced in patients with brain metastases, compared with patients without brain metastases, potentially due to tumor‐induced BBB disruption [35, 36], raising the question of whether small asymptomatic brain metastases could be treated with an EGFR‐TKI alone. The effect of WBRT on the BBB permeability of EGFR‐TKIs is unclear, with one study reporting an increase in the CSF:plasma ratio of gefitinib following WBRT [35] and another reporting no difference [33].

Despite preclinical data suggesting poor BBB penetrance, EGFR‐TKIs have demonstrated systemic efficacy and CNS activity in patients with brain metastases. In a meta‐analysis of eight clinical studies, EGFR‐TKIs in combination with SRS or WBRT were found to significantly improve objective response rate (ORR), time to CNS progression, and median OS, compared with radiotherapy without EGFR‐TKIs [37]. One phase II study of EGFR‐TKIs for brain metastases reported a systemic ORR of 83%; however, there was a high rate of intracranial disease progression. Of those patients experiencing disease progression, 62% progressed in intracranial lesions only and 19% in both intracranial and extracranial lesions [38]. However, compared with chemotherapy, EGFR‐TKIs are associated with a lower risk of progression in the CNS [39]. EGFR‐TKIs have shown promise in the treatment of LM, with retrospective studies indicating that EGFR‐TKIs can improve survival [2, 10]. An intermittent high dose, known as pulsatile dosing, has been trialed in an attempt to increase EGFR‐TKI concentrations in the CSF and has shown promise in treating patients with CNS metastases that are refractory to treatment with standard‐dose EGFR‐TKIs [40].

A major challenge with EGFR‐TKI treatment is the development of acquired resistance, which occurs in most patients treated with a first‐line first‐ or second‐generation EGFR‐TKI (i.e., gefitinib, erlotinib, afatinib) [41-43]. Although several mechanisms of resistance to EGFR‐TKI therapy have been identified, in more than 50% of cases, resistance is attributable to the EGFR T790M mutation [44-47]. However, research conducted using paired biopsies indicates that the distribution of T790M is spatially heterogeneous, with a lower frequency in the CNS compared with thoracic lesions [48, 49]. The comparative rarity of T790M in the CNS may be due to the relatively poor CNS penetration of EGFR‐TKIs [49]. Evidence suggests that mechanisms of resistance in CNS metastases may differ compared with those outside of the CNS [50, 51].

In recent years, novel EGFR‐TKIs, such as osimertinib and AZD3759, have been developed to address the challenges of acquired resistance and poor CNS penetration, respectively, that are experienced with first‐ and second‐generation EGFR‐TKIs [52-54]. A summary of ongoing clinical trials of EGFR‐TKIs for patients with CNS metastases from NSCLC is listed in Table 1. In the following sections, we discuss evidence for individual EGFR‐TKIs in CNS metastases.

Gefitinib

Gefitinib is the first EGFR‐TKI to be approved for the treatment of NSCLC, with initial approval granted for third‐line treatment of patients with advanced NSCLC, irrespective of EGFR‐mutation status, and subsequent approvals for first‐line treatment of patients with advanced EGFR‐mutated disease [28,55,56]. Preclinical data show that the distribution of [¹⁴C]gefitinib in the CNS of nontumor‐bearing mice (AstraZeneca, data on file) and pigmented rats is low [30]. [¹¹C]gefitinib also demonstrated low penetration in the nonhuman primate brain under positron emission tomography (PET) microdosing conditions [30], deemed robust methodology for predicting brain exposure [57]. In in vitro assays and a murine NSCLC brain metastases model, the CNS permeability and efflux ratio of gefitinib increased in a dose‐dependent manner. However, gefitinib is a substrate for P‐gp and, even at the highest dose tested (200 mg/kg), had limited BBB penetration [58]. Gefitinib has been shown to inhibit P‐gp in multidrug‐resistant lung cancer cells, suggesting it may be able to partially overcome this mechanism of drug resistance [59].

Despite its poor CNS penetration properties, preclinical studies have shown that gefitinib has CNS activity. In mice with EGFR overexpressing intracranial tumors, gefitinib treatment prolonged median survival, compared with no treatment (34 and 18 days, respectively) [29]. Durable responses to gefitinib have been reported in a case series of patients with brain metastases from EGFR‐mutated NSCLC [60]. In a phase II study (n = 41), intracranial ORR with gefitinib was 88%, with 13 patients (32%) experiencing a complete response (CR) [61]. The median time to CNS progression was 14.5 months, with an OS of 21.9 months; however, salvage radiotherapy was required in 49% of patients.

Erlotinib

Erlotinib is a first‐generation EGFR‐TKI recommended as an option for first‐line treatment of advanced EGFR‐mutated NSCLC [14]. As with gefitinib, preclinical studies have demonstrated that erlotinib exposure in the brain is limited [62]. The primary efflux mechanism for erlotinib has been identified as BCRP, with P‐gp having little effect [63]. Although erlotinib penetration of the BBB is normally limited, one case study reports increased accumulation of [¹¹C]erlotinib in brain lesions, compared with the cerebral cortex, of a patient with both brain metastases and LM from NSCLC [64]. Near complete remission of the patient's CNS metastases was achieved within 3 weeks of treatment initiation [64]. It is possible that, in some cases, tumor‐induced disruption of the BBB may allow for increased erlotinib penetration. In a retrospective analysis of 17 patients with brain metastases from EGFR‐mutated NSCLC treated with erlotinib, CNS ORR was 82% and median time to CNS progression was 11.7 months [65]. Of eight patients who did not receive WBRT and were treated with erlotinib alone, six (75%) had objective responses (four CR, two partial responses).

Several case series have reported promising efficacy with high‐dose erlotinib for the treatment of CNS metastases (including LM) refractory to EGFR‐TKIs administered at conventional doses [40,66,67]. In a retrospective analysis of nine patients with CNS metastases from EGFR‐mutated NSCLC treated with high‐dose erlotinib (900–1500 mg weekly), six (67%) patients had a partial radiographic response. Median time to CNS progression was 2.7 months and OS was 12 months after initiation of high‐dose erlotinib [40]. Another small case series reported radiographic responses in four of five (80%) evaluable patients treated with high‐dose erlotinib, with one patient showing a CR of both brain metastases and LM [66]. Excluding a patient with prolonged survival who received combination therapy, median OS was 4 months (range 2.5–15 months). The efficacy of high‐dose erlotinib in patients with LM is further discussed in the leptomeningeal metastases section.

Afatinib

Afatinib is a second‐generation EGFR‐TKI and was approved as first‐line treatment for EGFR‐mutated advanced NSCLC in the U.S. in 2013. Preclinical studies of afatinib have shown that exposure in the brain is low, with a brain:plasma maximum observed plasma concentration (C_max) ratio of <0.36 for a clinically relevant dose of afatinib [30]. However, afatinib has been shown to penetrate the BBB in a murine model of brain metastases from NSCLC and, despite low CNS exposure, cause intracranial tumor regression [68].

The overall response to afatinib in patients with brain metastases has been assessed in subset analyses of phase II and phase III trials. In the phase II LUX‐Lung 2 trial, the ORR was similar between patients with and without brain metastases (65% vs. 60%) [69]. A subgroup analysis of patients with brain metastases included in the phase III LUX‐Lung 3 and LUX‐Lung 6 trials revealed significant improvements in systemic ORR for patients treated with afatinib compared with chemotherapy (70% vs. 20% and 75% vs. 28%, respectively) [70]. The intracranial response rate was not assessed in either study. In an exploratory combined analysis of both studies, progression‐free survival (PFS) was longer with afatinib than with chemotherapy (8.2 vs. 5.4 months; hazard ratio [HR] 0.50; 95% confidence interval [CI] 0.27–0.95; p = .0297). The PFS benefit with afatinib was found to be higher in those patients who received prior WBRT (13.8 vs. 4.7 months) compared with patients who did not (6.9 vs. 5.4 months) [70]. Further studies are required to establish the CNS efficacy of afatinib.

Icotinib

Icotinib is a novel EGFR‐TKI approved for the second‐ or third‐line treatment of advanced NSCLC by the State Food and Drug Administration of the People's Republic of China [71]. Preclinical data on the ability of icotinib to cross the BBB are lacking; however, CSF penetration in patients with brain metastases from NSCLC has been reported as 1.2%–9.7% across three different dose levels (125–500 mg), with a significant correlation between icotinib concentration in the CSF and plasma [72]. WBRT was found to not impact the CSF penetration of icotinib. In a phase III trial (n = 176), icotinib demonstrated superior efficacy over WBRT and chemotherapy for patients with brain metastases from EGFR‐mutated NSCLC [73]. Intracranial PFS was 10 months with icotinib versus 4.8 months with WBRT plus chemotherapy (HR 0.56; 95% CI 0.36–0.90; p = .014). Intracranial ORR was also significantly improved with icotinib, compared with WBRT and chemotherapy (65% vs. 37%, respectively; p = .001), although there was no difference in OS (18 vs. 20.5 months; p = .734).

Osimertinib

Osimertinib is a potent, CNS‐active, irreversible EGFR‐TKI selective for EGFR‐TKI‐sensitizing mutations and the EGFR T790M resistance mutation [30,52,74,75]. Osimertinib initially gained U.S. Food and Drug Administration approval based on a pooled analysis of two phase II studies (AURA extension and AURA2) demonstrating a response rate of 66% in patients with EGFR T790M mutations who were refractory to EGFR‐TKI treatment [76, 77]. Osimertinib is now recommended in the NCCN Guidelines for NSCLC as first‐line treatment for patients with EGFR‐mutated NSCLC and as second‐line treatment for patients with T790M‐positive disease following progression on erlotinib, gefitinib, or afatinib [14]. Preclinical development of osimertinib specifically focused on the assessment of brain penetration and CNS activity. Despite being a substrate of the efflux transporters P‐gp and BCRP, osimertinib is more highly distributed than gefitinib, rociletinib, and afatinib in the mouse brain, with a brain:plasma C_max ratio of 3.41 versus 0.21, <0.08 and <0.36, respectively [30]. Osimertinib is also highly distributed in the nonhuman primate brain, with greater exposure than rociletinib and gefitinib [30].

In the phase III AURA3 trial, osimertinib demonstrated significantly greater systemic efficacy than chemotherapy in patients with T790M‐positive NSCLC, including those patients with CNS metastases [78]. In a prespecified subgroup analysis, CNS ORR in patients with measurable CNS lesions (n = 46) was 70% with osimertinib, compared with 31% with chemotherapy (p = .015). In patients with measurable and/or nonmeasurable CNS lesions (n = 116), median CNS PFS was significantly longer with osimertinib compared with chemotherapy (11.7 vs. 5.6 months; HR 0.32; 95% CI 0.15–0.69; p = .004) [79]. The recent FLAURA study compared osimertinib with standard‐of‐care EGFR‐TKI (erlotinib or gefitinib) as first‐line therapy in patients with advanced EGFR‐mutated NSCLC; treatment with osimertinib resulted in significantly longer systemic PFS across all predefined subgroups, including those patients with known or treated CNS metastases (median 15.2 vs. 9.6 months; HR 0.47; 95% CI 0.30–0.74; p < .001) [80]. There was a lower incidence of CNS progression events with osimertinib versus standard of care (6% vs. 15%), irrespective of presence or absence of known or treated CNS metastases at study entry. In a subgroup analysis of patients with CNS metastases at baseline, as assessed by neuroradiological blinded independent central review, there was a 52% reduction in the risk of CNS progression with osimertinib (HR 0.48; 95% CI 0.26–0.86; p = .014 [nominally statistically significant]), confirming that osimertinib is superior to erlotinib and gefitinib in the control of CNS metastases [81].

In a subgroup analysis of patients with CNS metastases at baseline, as assessed by neuroradiological blinded independent central review, there was a 52% reduction in the risk of CNS progression with osimertinib, confirming that osimertinib is superior to erlotinib and gefitinib in the control of CNS metastases.

AZD3759

AZD3759 represents a novel class of EGFR‐TKI, which is not a substrate of the efflux transporters P‐gp or BCRP. This compound, which was specifically developed to achieve high exposure both in the plasma and in the CNS by penetrating the BBB, is under investigation for the treatment of CNS metastases from NSCLC [54,82,83]. AZD3759 has an unbound brain exposure:unbound plasma ratio of 0.86, indicating similar free exposure in the brain and plasma [83]. In a mouse PC‐9 (EGFR exon 19 deletion) xenograft brain metastases model, AZD3759 induced profound tumor regression and significantly improved survival [53, 82]. The efficacy of AZD3759 in patients with CNS metastases is currently being evaluated in the ongoing phase I BLOOM study (NCT02228369). In an EGFR‐TKI‐naïve cohort, intracranial ORR was 63% (12 of 19 evaluable patients) and systemic ORR 60% (12 of 20 evaluable patients) [84].

Leptomeningeal Disease

The NCCN Guidelines for NSCLC recommend osimertinib (regardless of T790M status) or weekly pulse erlotinib for patients with EGFR‐mutated NSCLC and progressive LM [14]. Osimertinib has shown promising activity in patients with LM, with a number of case studies reporting the efficacy of osimertinib 80 mg once daily for treating patients with refractory LM following prior treatment with EGFR‐TKIs, chemotherapy, SRS, and WBRT [85-89]. The efficacy of osimertinib 160 mg once daily for patients with heavily pretreated LM is also being assessed in the phase I BLOOM study. In an interim analysis of 23 patients who reached a 12‐week brain imaging assessment, 10 patients had radiological improvement and 13 had stable disease [90]. The efficacy of AZD3759 is being investigated in the same study; in the EGFR‐TKI pretreated cohort, 53% of 17 evaluable patients had confirmed improved or stable LM on radiographic assessment, and two of three patients with concomitant measurable brain metastases achieved confirmed/unconfirmed partial CNS response [91].

Both high‐dose erlotinib and gefitinib have shown promise in treating LM. In a phase II study of erlotinib for patients with LM (n = 21), 35% of 17 patients with EGFR‐mutated disease achieved complete CSF cytological clearance. Median time to LM progression and OS were 2.7 and 4 months, respectively [92]. In a small phase I trial (n = 7) of high‐dose gefitinib (750 mg or 1,000 mg daily) for 2 weeks, followed by 2 weeks of maintenance therapy (500 mg daily), no patients showed radiological improvement. However, four patients had neurological improvement and one had complete CSF cytological clearance. Median PFS and OS were 2.3 and 3.5 months, respectively [93].

Several small studies suggest that erlotinib may be more effective than gefitinib for the treatment of patients with LM [32,94,95], and, in a retrospective review of 22 patients who received erlotinib (n = 17) or gefitinib (n = 5) for the treatment of LM from EGFR‐mutated NSCLC, median PFS was longer in patients treated with erlotinib compared with gefitinib (6.6 vs. 2.1 months; p = .07). Median OS with erlotinib was more than double the OS achieved with gefitinib (7.2 vs. 3.0 months; p = .32) [95]. Case studies also suggest that erlotinib may have value in treating patients who have LM progression with gefitinib [34, 96].

There is limited evidence for the efficacy of other EGFR‐TKIs for the treatment of LM. Evidence for the efficacy of afatinib in LM is limited to case reports, which have described successful treatment of LM [97-100]. In a retrospective review of standard‐ or double‐dose icotinib for LM from NSCLC, 81% of 21 patients had improved Eastern Cooperative Oncology Group performance status, and median OS was 10.1 months [101]. However, as this was a small retrospective study, and patients received additional therapies for the treatment of LM, further studies are required to confirm the potential benefit of icotinib in this setting.

Treating CNS Metastases: Challenges and Future Directions

Clinical Trial Endpoints

The selection of the most appropriate endpoints for clinical trials in patients with CNS metastases is challenging, given the need to account for both CNS and systemic disease. OS may not be an optimal endpoint, as death due to systemic disease progression, despite stable CNS disease, is common [102, 103]. If PFS is used as an endpoint, a clear distinction between CNS, non‐CNS, and systemic PFS should be made. However, an accurate assessment of intracranial PFS can be difficult to achieve after SRS, as radionecrosis can resemble disease recurrence [102]. Furthermore, if systemic disease progression occurs, assessments of CNS progression often ceases, censoring CNS or overall PFS results. As an alternative approach, some studies have employed neurocognitive outcomes as a primary endpoint [104].

RECIST World Health Organization tumor response criteria, and Response Assessment in Neuro‐Oncology (RANO) are commonly used in clinical trials to measure response to treatment. However, patients with CNS metastases have traditionally been excluded from clinical trials, and, when included, there has been a lack of standardization of response assessment [105, 106]. The previously mentioned criteria were not designed to assess CNS response and, therefore, have major limitations in this setting. In particular, unstandardized neuroimaging criteria and nonspecific shrinkage measurements make it difficult to determine a uniformly measured response that can be robustly compared across clinical trials [102]. To address these limitations, additional, specific RANO criteria have been proposed [107]. The RANO criteria for the assessment of brain metastases takes radiographic responses, corticosteroid use, and clinical status into account for response assessment [106]. It is hoped that these criteria will facilitate the development of novel, consistent approaches for the evaluation of CNS metastases.

Traditional efficacy endpoints are challenging to apply in clinical trials of LM as cause of death is usually difficult to determine and patients often have simultaneous progression of both CNS and systemic disease. Consequently, the most suitable endpoint to evaluate treatment efficacy in this population may be time to neurological disease progression.

Traditional efficacy endpoints are challenging to apply in clinical trials of LM as cause of death is usually difficult to determine and patients often have simultaneous progression of both CNS and systemic disease. Consequently, the most suitable endpoint to evaluate treatment efficacy in this population may be time to neurological disease progression [108]. There is currently no validated quantitative radiographic method to assess LM. False‐negative results are common with CSF cytology analysis [109] and neuroimaging [110, 111], making response difficult to determine in these patients. In addition, the absence of a uniform approach to treatment decisions makes the determination of suitable candidates for LM trials difficult. There has been a lack of standardization in clinical trials for LM, with heterogeneity in trial endpoints and response assessments [108]. To address these challenges, the RANO LM working group have developed a consensus proposal for LM response assessment, with the aim of standardizing neurological, CSF cytology, and radiographic assessments [112]. These novel response criteria have not yet been validated and may require further refinement.

Treatment Sequence

The results of the recent FLAURA study, which demonstrate osimertinib's superiority over erlotinib and gefitinib in the first‐line setting [80], raise the question of optimal EGFR‐TKI sequencing. If reserved for those patients with disease progression following first‐line EGFR‐TKIs, osimertinib may extend PFS and offer patients another line of treatment. However, the superior CNS control with osimertinib, and potential to prevent the development of CNS metastases, support its up‐front use. Furthermore, reserving osimertinib for second‐line treatment may limit the patient population that can provide a benefit from this agent. Although more than 50% of patients will have T790M‐positive tumors on progression [44-47], some may not be suitable for rebiopsy [113] or second‐line therapy. Previous clinical trial reports suggest that as many as 20%–50% of patients with EGFR‐mutated NSCLC do not receive any poststudy treatment after discontinuation, due to aggressive disease progression [114-116].

The optimal treatment sequence for patients with CNS metastases from EGFR‐mutated NSCLC is not clear. In a retrospective analysis of patients who developed brain metastases before initiating therapy with an EGFR‐TKI (erlotinib in 98% of patients), SRS followed by EGFR‐TKI was associated with a greater OS than WBRT followed by EGFR‐TKI (median 47 vs. 31 months) [117]. However, the use of an up‐front EGFR‐TKI, and deferral of SRS or WBRT, was associated with an inferior OS (median 25 months). To confirm these findings, a prospective randomized trial of SRS followed by EGFR‐TKI, compared with EGFR‐TKI followed by SRS at CNS progression, is needed. Concurrent WBRT and EGFR‐TKI treatment has been shown to be effective in phase II trials of erlotinib, gefitinib, and icotinib for the treatment of brain metastases from NSCLC, with an acceptable tolerability profile. In a phase II trial (n = 21) of gefitinib administered concurrently with WBRT, intracranial ORR was 81% in patients with measurable lesions; median PFS and OS were 10 and 13 months, respectively [118]. Erlotinib administered concurrently with WBRT has demonstrated a CNS ORR of 86% and a median CNS PFS of 8 months in a phase II study (n = 40). For patients with EGFR‐mutated disease, median survival time was 19.1 months [119]. In a study of icotinib plus WBRT (n = 20), intracranial ORR was 80%. Median PFS and OS for patients with EGFR‐mutated disease were 12 and 22 months, respectively [120]. However, given the limitations of WBRT, further research is needed to assess whether the addition of WBRT to EGFR‐TKI treatment improves outcomes, compared with EGFR‐TKI alone for patients with CNS metastases from EGFR‐mutated disease.

Novel Diagnostic Approaches to Assess BBB Penetrance

EGFR‐TKIs with improved BBB‐penetrating properties could have benefits in both treating and preventing CNS metastases [121]; however, developing drugs with good BBB‐penetrating properties and accessing the CNS sanctuary site remains a challenge. Radiolabeling EGFR‐TKIs for PET microdosing studies provides an opportunity to evaluate BBB penetration and brain exposure. To date, this approach has been limited to the preclinical assessment of EGFR‐TKIs [30, 62]. However, such studies can also be performed in healthy volunteers and patients with brain metastases from NSCLC, in whom the BBB may be compromised. Although the tracer doses used in PET microdosing studies do not reflect the brain exposure of therapeutic doses, the utility of this approach for assessing BBB penetration and brain distribution in humans has been established using sertraline [122].

Conclusion

Despite the challenge of BBB penetration, initial CNS responses in treatment‐naïve patients are common following treatment with EGFR‐TKIs alone. Novel EGFR‐TKIs developed to improve CNS penetration, such as osimertinib, show encouraging efficacy in controlling CNS disease, and personalized biomarker‐driven treatment strategies will continue to maximize benefit to individual patients [78, 123-128]. Although recent studies suggest that deferring radiotherapy may be associated with comparatively inferior survival, combined treatment approaches have demonstrated efficacy and an adequate safety profile. Therefore, the treatment of CNS metastases from EGFR‐mutant NSCLC requires a multidisciplinary approach to define optimal treatment options or sequence of therapies for individual patients. Given the evolving treatment paradigm for these patients, treatment decisions must be individualized, factoring in the patient's performance status, CNS disease burden, and clinical symptoms in the context of a critical risk‐benefit analysis. Looking to the future, clinical trial endpoints need to clearly differentiate between CNS and systemic disease progression, be tailored to the trial setting, type of therapy under investigation, patient population, and EGFR‐mutation status, and be used consistently across studies. The use of a rational, iterative approach to the drug development process allows the design of agents with the intention of overcoming the BBB and holds promise for preventing morbidity and mortality attributable to CNS disease progression.

Acknowledgments

We acknowledge Rosalie Richards, Ph.D., and Rebecca Plant, M.Sc., of iMed Comms, Macclesfield, an Ashfield Company, part of UDG Healthcare plc, for medical writing support that was funded by AstraZeneca, U.K., in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Author Contributions

Conception/design: Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy

Collection and/or assembly of data: Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy

Data analysis and interpretation: Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy

Manuscript writing: Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy

Final approval of manuscript: Manmeet S. Ahluwalia, Kevin Becker, Benjamin P. Levy

Disclosures

Manmeet S. Ahluwalia: Monteris Medical, AstraZeneca, Bristol‐Myers Squibb, CBT Pharmaceuticals, Kadmon Pharmaceuticals, Abbvie, VBI Vaccines (C/A), AstraZeneca, Bristol‐Myers Squibb, Novocure, Novartis, Incyte, Abbvie, Pharmacylics (RF), Elsevier, Prime Oncology (H); Kevin Becker: AstraZeneca (C/A), Genentech/Roche, Bristol‐Myers Squibb (RF); Benjamin P. Levy: AstraZeneca, Eli Lilly, Roche (C/A).

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

References

Author notes